Show summary Hide summary
A sudden cluster of federal meetings this month pushed menopause from background chatter into policy talks in Washington — and raised an immediate question: will the momentum translate to concrete changes in research, training and access to care? Lawmakers, agency officials and patients all signaled that this is more than a fleeting interest; it may reshape how clinicians and insurers treat midlife women.
Across three high-profile gatherings Sept. 15–17, officials zeroed in on hormone therapies and the clinical gaps that leave many women waiting months or years for effective help. The sessions—hosted by the Department of Health and Human Services, the Senate Special Committee on Aging and the Food and Drug Administration—combined patient testimony, clinical appeals and calls for expanded study.
What unfolded in Washington
On Sept. 15, Health and Human Services leaders met with doctors and manufacturers to discuss expanding access to estrogen patches and to highlight alternative treatment approaches for clinicians. That same day the Senate panel held its first-ever hearing devoted to menopause, spotlighting the sparse research base and the need to train a broader range of providers beyond gynecologists.
Boxing champions ditch long runs for high-intensity training: new era in fight prep
Czech nationals among victims of Pinedale-area crash: two confirmed dead
Two days later the FDA gathered experts to examine the potential role of testosterone in women’s care, a topic drawing renewed attention for its links to libido, bone health, muscle mass, mood and cognition.
At the FDA session Dr. Rachel Rubin, a urologist who treats sexual health, demonstrated topical application of testosterone and urged federal regulators to prioritize evaluation of the drug for women — an approval that could affect insurance coverage and pharmacy availability.
Why this matters now
Patients and advocates described routine dismissal and misdiagnosis during the hearings: symptoms labeled anxiety and treated with antidepressants, pain attributed to lifestyle, sexual discomfort minimized or trivialized. Those experiences, they said, often delay care that could reduce long-term risks such as heart disease and osteoporosis.
Speakers repeatedly returned to two interconnected problems: a shortage of research on menopausal treatments, and limited clinical training so that primary care providers, internists and other specialists can recognize and treat midlife hormonal changes.
- Access gaps: Testosterone is commonly prescribed off-label for women, which can mean inconsistent insurance coverage and pharmacy refusal.
- Diagnostic delays: Surveys cited during the meetings found many women wait months to a year before a menopause diagnosis; a small share reported seeing more than ten clinicians before getting help.
- Clinical scope: Leaders argued menopause care must extend beyond symptom relief to prevention of long-term health consequences.
Voices from the hearings
Susan Lake, who works in construction and design, told regulators that persistent hot flashes, insomnia and depression undermined her job performance. After consultations with multiple specialists she finally found a clinician who listened and was prescribed hormone therapy that included testosterone.
Experts urged federal action that would back more studies into hormonal therapy outcomes and broaden provider training so patients don’t have to navigate a patchwork of dismissive responses. As one women’s health advocate put it during the Senate session, attention to menopause should be sustained policy and clinical work—not a passing trend.
Clinicians also emphasized practical obstacles: because testosterone has not been FDA-approved for women, many insurers deny coverage and some pharmacies decline to fill prescriptions even when clinicians deem them appropriate.
Next steps policymakers and patients want to see
Advocates and clinicians at the meetings sketched a near-term agenda that focused on evidence and education. Common proposals included:
- Funding targeted clinical trials on hormonal therapies and long-term outcomes.
- Expanding training modules on midlife care across primary care, urology, endocrinology and geriatrics.
- Clarifying regulatory pathways so insurance coverage and pharmacy access align with clinical practice.
- Raising public awareness so women recognize symptoms and know where to seek care.
Regulatory momentum already has a grassroots component: when the FDA convened a meeting on testosterone for men in 2025, a large share of public comments were submitted by women describing their own experiences and needs — an unusual public pressure point that helped prompt the recent expert discussions.
The central message from Washington was consistent: increasing visibility is only the first step. Turning attention into better clinical guidelines, more robust research and reliable access will require coordinated action from agencies, medical schools, insurers and pharmacies.
Laura Trujillo is a national columnist covering health and wellness.
